Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups;Efecto de AM3 en la calidad de vida de pacientes con enfermedad pulmonar obstructiva crónica en subgrupos de riesgo

Medicina Clinica

Volumn 130, Issue 18, 2008, Pages 688-692

  Miravitlles, Marc ^a   Murio, Cristina ^b   Morera, Josep ^c   Callol, Luis ^d   Álvarez Sala, José Luis ^d   Álvarez Mon, Melchor ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL GENERAL DE CATALUNYA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

AM3; COPD; Exacerbation; Quality of life; St. George's respiratory questionnaire

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IMMUNOFERON; PLACEBO; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RISK POPULATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 45249090111     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13120769     Document Type: Article

References (25)

1. Sobradillo V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest. 2000;118:981-9.
2. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med. 1997;127:1072-9.
3. González Constán E, Herrejón Silvestre A, Inchaurraga Álvarez I, Palop Medina J, Blanquer Olivas R. Relación de la disnea y la calidad de vida con el índice de masa corporal y la función pulmonar en pacientes con enfermedad pulmonar obstructiva crónica tipo enfisema. Med Clin (Barc). 2001;117:370-1.
4. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321-7.
5. Prieto A, Reyes E, Bernstein ED, Martínez B, Monserrat J, Izquierdo JL, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Inmunoferon). Am J Respir Crit Care Med. 2001;163:1578-83.
6. Reyes E, Prieto A, De la Hera A, De Lucas P, Álvarez-Sala R, Álvarez-Sala JL, et al. Treatment with AM3 restores defective T-cell function in COPD patients. Chest. 2006;129:527-35.
7. Álvarez-Mon M, Miravitlles M, Morera J, Callol L, Álvarez-Sala JL. Treatment with the immunomodulator AM3 improves the health-related quality of life of patients with COPD. Chest. 2005;127:1212-8.
8. Ferrer M, Alonso J, Prieto L, Plaza V, Monsó E, Marrades R, et al. Validity and reliability of the St George's Respiratory Questionnaire alter adaptation to a different language and cultura: the Spanish example. Eur Respir J. 1996;9:1160-6.
9. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19:398-404.
10. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-22.
11. Doll H, Miravitlles M. Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: A review of the literature. Pharmacoeconomics. 2005;23:345-63.
12. Miravitlles M, Ferrer M, Pont A, Zalacain R, Álvarez-Sala JL, Masa JF, et al. Effect of exacerbations on quality of life in patines with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59:387-95.
13. Reyes E, Fernández C, Álvarez-Sala JL, Álvarez-Mon M. Efecto del inmunomodulador AM3 sobre las agudizaciones en enfermos con bronquitis crónica: una revisión sistemática de estudios controlados. Rev Clin Esp. 2004;204:466-71.
14. Steurer-Stey C, Bachmann LM, Steurer J, Tramèr MR. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest. 2004;126:1645-55.
15. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:736-43.
16. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J. 2005;25:552-63.
17. Decramer M, Rutten-van Mölken M, Dekhuijzen PNR, Troosters T, Van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomised on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365:1552-60.
18. Van Andel AE, Reisner C, Menjoge SS, Witek TJ. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Chest. 1999;115:703-7.
19. Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest. 2003;123:784-91.
20. Miravitlles M, Calle M, Álvarez-Gutiérrez F, Gobartt E, López F, Martín A, and the EIME group. Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease. Qual Life Res. 2006;15:471-80.
21. Spencer S, Calverley PMA, Burge PS, Jones PW on behalf of the ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonay disease. Am J Respir Crit Care Med. 2001;163:122-8.
22. Oga T, Nishimura K, Tsukino M, Hajiro T, Sato S, Ikeda A, et al. Longitudinal changes in health status using the Chronic Respiratory Disease Questionnaire and pulmonary function in patients with stable Chronic Obstructive Pulmonary Disease. Qual Life Res. 2004;13:1109-16.
23. Vega Reyes JA, Montero Pérez-Barquero M, Sánchez Guijo P. Factores pronósticos de reingreso en la enfermedad pulmonar obstructiva crónica. Med Clin (Barc). 2004;122:293-7.
24. Soler JJ, Sánchez L, Román P, Martínez MA, Perpiñá M. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir Med. 2004;98:318-29.
25. Domingo-Salvany A, Lamarca R, Ferrer M, García-Aymerich J, Alonso J, Félez M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166: 680-5.